Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer.

TitleElevated expression of UBE2T exhibits oncogenic properties in human prostate cancer.
Publication TypeJournal Article
Year of Publication2015
AuthorsWen M, Kwon Y, Wang Y, Mao J-H, Wei G
JournalOncotarget
Volume6
Issue28
Pagination25226-39
Date Published2015 Sep 22
ISSN1949-2553
KeywordsCell Line, Tumor, Cell Movement, Cell Proliferation, Epithelial-Mesenchymal Transition, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Heterografts, Humans, Kaplan-Meier Estimate, Male, Neoplasm Invasiveness, Neoplasm Transplantation, Prognosis, Prostatic Neoplasms, RNA Interference, Signal Transduction, Time Factors, Transfection, Ubiquitin-Conjugating Enzymes, Up-Regulation
Abstract

Increased expression of ubiquitin-conjugating enzyme E2T (UBE2T) is reported in human prostate cancer. However, whether UBE2T plays any functional role in prostate cancer development remains unknown. We here report the first functional characterization of UBE2T in prostate carcinogenesis. Prostate cancer tissue array analysis confirmed upregulation of UBE2T in prostate cancer, especially these with distant metastasis. Moreover, higher level of UBE2T expression is associated with poorer prognosis of prostate cancer patients. Ectopic expression of UBE2T significantly promotes prostate cancer cell proliferation, motility and invasion, while UBE2T depletion by shRNA significantly inhibits these abilities of prostate cancer cells. Xenograft mouse model studies showed that overexpression of UBE2T promotes whereas UBE2T depletion inhibits tumor formation and metastasis significantly. Collectively, we identify critical roles of UBE2T in prostate cancer development and progression. These findings may serve as a framework for future investigations designed to more comprehensive determination of UBE2T as a potential therapeutic target.

DOI10.18632/oncotarget.4712
Alternate JournalOncotarget
PubMed ID26308072
PubMed Central IDPMC4694827
Grant ListR01 CA116481 / CA / NCI NIH HHS / United States
R01 CA116481 / CA / NCI NIH HHS / United States